I agree that this site is using cookies. You can find further informations here.
X
Freyer, Gilles
174  results:
Search for persons X
?
1

Single-agent metronomic versus weekly oral vinorelbine as f..:

Freyer, Gilles ; Martinez-Jañez, Noelia ; Kukielka-Budny, Bożena...
The Breast.  74 (2024)  - p. 103681 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Progression-free survival and safety at 3.5 years of follow..:

González-Martín, Antonio ; Pothuri, Bhavana ; Vergote, Ignace...
Future Oncology.  , 2024
Link: https://doi.org/10.2217/..
 
?
3

Bevacizumab, olaparib, and durvalumab in patients with rela..:

Freyer, Gilles ; Floquet, Anne ; Tredan, Olivier...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
4

Confirmation of the utility of the CA-125 elimination rate ..:

van Wagensveld, Lilian ; Colomban, Olivier ; van der Aa, Maaike A....
Journal of Gynecologic Oncology.  35 (2024)  3 - p. , 2024
Link: https://doi.org/10.3802/..
 
?
5

Author Correction: Bevacizumab, olaparib, and durvalumab in..:

Freyer, Gilles ; Floquet, Anne ; Tredan, Olivier...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
6

Identification of Patients with Early HR+ HER2− Breast Canc..:

Fasching, Peter A. ; Kreipe, Hans ; Del Mastro, Lucia...
Geburtshilfe und Frauenheilkunde.  84 (2024)  2 - p. 164-184 , 2024
Link: https://doi.org/10.1055/..
 
?
7

Mathematical modeling of the early modeled CA-125 longitudi..:

Colomban, Olivier ; Swisher, Elizabeth M. ; Kristeleit, Rebecca...
eBioMedicine.  89 (2023)  - p. 104477 , 2023
Link: https://doi.org/10.1016/..
 
?
8

Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated..:

Bellier, Charlotte ; Gladieff, Laurence ; Le Du, Fanny...
Drugs - Real World Outcomes.  10 (2023)  2 - p. 207-213 , 2023
Link: https://doi.org/10.1007/..
 
?
9

Avelumab in patients with gestational trophoblastic tumors ..:

You, Benoit ; Bolze, Pierre-Adrien ; Lotz, Jean-Pierre...
Gynecologic Oncology.  168 (2023)  - p. 62-67 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PAR..:

Antherieu, Gabriel ; Heiblig, Maël ; Freyer, Gilles..
Drugs & Aging.  40 (2023)  5 - p. 397-405 , 2023
Link: https://doi.org/10.1007/..
 
?
11

HER2-Positive Metastatic Breast Cancer: Available Treatment..:

Essadi, Ismail ; Benbrahim, Zineb ; Kaakoua, Mohamed...
Cancers.  15 (2023)  6 - p. 1738 , 2023
Link: https://doi.org/10.3390/..
 
?
12

Clinical results of the EVESOR trial, a multiparameter phas..:

Varnier, Romain ; Puszkiel, Alicja ; Tod, Michel...
Cancer Chemotherapy and Pharmacology.  91 (2023)  5 - p. 361-373 , 2023
Link: https://doi.org/10.1007/..
 
?
13

Progression-free survival and safety at 3.5 years of follow..:

González-Martín, Antonio ; Pothuri, Bhavana ; Vergote, Ignace...
European Journal of Cancer.  189 (2023)  - p. 112908 , 2023
Link: https://doi.org/10.1016/..
 
?
14

A PK-PD model linking biomarker dynamics to progression-fre..:

Puszkiel, Alicja ; You, Benoit ; Payen, Léa...
Cancer Chemotherapy and Pharmacology.  91 (2023)  5 - p. 413-425 , 2023
Link: https://doi.org/10.1007/..
 
?
15

Assessment of Patient Reported Outcomes (PROs) in Outpatien..:

Collomb, Bastien ; Dubromel, Amélie ; Caffin, Anne Gaëlle...
Cancers.  14 (2022)  3 - p. 660 , 2022
Link: https://doi.org/10.3390/..
 
1-15